Abstract
Altered glucose metabolism in cancer cells is termed the Warburg effect, which describes the propensity of most cancer cells to take up glucose avidly and convert it primarily to lactate, despite available oxygen1,2. Notwithstanding the renewed interest in the Warburg effect, cancer cells also depend on continued mitochondrial function for metabolism, specifically glutaminolysis that catabolizes glutamine to generate ATP and lactate3. Glutamine, which is highly transported into proliferating cells4,5, is a major source of energy and nitrogen for biosynthesis, and a carbon substrate for anabolic processes in cancer cells, but the regulation of glutamine metabolism is not well understood1,6. Here we report that the c-Myc (hereafter referred to as Myc) oncogenic transcription factor, which is known to regulate microRNAs7,8 and stimulate cell proliferation9, transcriptionally represses miR-23a and miR-23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells. This leads to upregulation of glutamine catabolism10. Glutaminase converts glutamine to glutamate, which is further catabolized through the tricarboxylic acid cycle for the production of ATP or serves as substrate for glutathione synthesis11. The unique means by which Myc regulates glutaminase uncovers a previously unsuspected link between Myc regulation of miRNAs, glutamine metabolism, and energy and reactive oxygen species homeostasis.
Similar content being viewed by others
References
Deberardinis, R. J., Sayed, N., Ditsworth, D. & Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54–61 (2008)
Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13, 472–482 (2008)
DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345–19350 (2007)
Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J. Biol. Chem. 254, 2669–2676 (1979)
Gallagher, F. A., Kettunen, M. I., Day, S. E., Lerche, M. & Brindle, K. M. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn. Reson. Med. 60, 253–257 (2008)
Curthoys, N. P. & Watford, M. Regulation of glutaminase activity and glutamine metabolism. Annu. Rev. Nutr. 15, 133–159 (1995)
Chang, T. C. et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genet. 40, 43–50 (2008)
O’Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V. & Mendell, J. T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839–843 (2005)
Eilers, M. & Eisenman, R. N. Myc’s broad reach. Genes Dev. 22, 2755–2766 (2008)
Kita, K., Suzuki, T. & Ochi, T. Down-regulation of glutaminase C in human hepatocarcinoma cell by diphenylarsinic acid, a degradation product of chemical warfare agents. Toxicol. Appl. Pharmacol. 220, 262–270 (2007)
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R. & Lazebnik, Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178, 93–105 (2007)
Li, F. et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225–6234 (2005)
Schuhmacher, M. et al. Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. 9, 1255–1258 (1999)
Lombardi, L., Newcomb, E. W. & Dalla-Favera, R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 49, 161–170 (1987)
Gurel, B. et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 21, 1156–1167 (2008)
Perez-Gomez, C. et al. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem. J. 386, 535–542 (2005)
Turner, A. & McGivan, J. D. Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem. J. 370, 403–408 (2003)
Berns, K., Hijmans, E. M., Koh, E., Daley, G. Q. & Bernards, R. A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts. Oncogene 19, 3330–3334 (2000)
Nikiforov, M. A. et al. Complementation of Myc-dependent cell proliferation by cDNA expression library screening. Oncogene 19, 4828–4831 (2000)
Lora, J. et al. Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. Eur. J. Biochem. 271, 4298–4306 (2004)
Matsuno, T., Satoh, T. & Suzuki, H. Prominent glutamine oxidation activity in mitochondria of avian transplantable hepatoma induced by MC-29 virus. J. Cell. Physiol. 128, 397–401 (1986)
Porkka, K. P. et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 67, 6130–6135 (2007)
Landgraf, P. et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401–1414 (2007)
Bode, B. P. Recent molecular advances in mammalian glutamine transport. J. Nutr. 131, 2475S–2485S (2001)
Lobo, C. et al. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem. J. 348, 257–261 (2000)
Rabilloud, T. et al. The mitochondrial antioxidant defence system and its response to oxidative stress. Proteomics 1, 1105–1110 (2001)
Anderson, T. J. et al. Discovering robust protein biomarkers for disease from relative expression reversals in 2-D DIGE data. Proteomics 7, 1197–1207 (2007)
Kersey, P. J. et al. The International Protein Index: an integrated database for proteomics experiments. Proteomics 4, 1985–1988 (2004)
Yates, J. R., Eng, J. K., McCormack, A. L. & Schieltz, D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal. Chem. 67, 1426–1436 (1995)
Gao, P. et al. HIF-dependent antitumorigenic effect of antioxidants in vivo . Cancer Cell 12, 230–238 (2007)
Acknowledgements
The authors want to thank L. Blosser and A. Tam for their help in flow cytometry analysis, and H. Y. Zhang for her help with statistical analysis. This work was partially supported by NIH Awards NHLBI NO1-HV-28180, NCI R01CA051497, NCI R01CA57341, NCI R01CA120185, NCI P50CA58236, Rita Allen Foundation, Leukemia and Lymphoma Society, and Sol Goldman Center for Pancreatic Cancer Research.
Author Contributions P.G., K.K., T.O., A.M.D., J.E.V., J.T.M. and C.V.D. designed experiments. P.G., I.T., T.-C.C., Y.-S.L. and K.I.Z. performed experiments. K.K. and T.O. provided reagents. P.G. and C.V.D. wrote the paper. All authors discussed the results and commented on the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Supplementary information
Supplementary Information
This file contains Supplementary Figures S1-S10 with Legends and Supplementary Tables S1-S2 (PDF 410 kb)
Rights and permissions
About this article
Cite this article
Gao, P., Tchernyshyov, I., Chang, TC. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762–765 (2009). https://doi.org/10.1038/nature07823
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature07823
- Springer Nature Limited
This article is cited by
-
The microRNA-211-5p/P2RX7/ERK/GPX4 axis regulates epilepsy-associated neuronal ferroptosis and oxidative stress
Journal of Neuroinflammation (2024)
-
SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer
Breast Cancer (2024)
-
Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study
BMC Cancer (2023)
-
CAFs targeted ultrasound-responsive nanodroplets loaded V9302 and GLULsiRNA to inhibit melanoma growth via glutamine metabolic reprogramming and tumor microenvironment remodeling
Journal of Nanobiotechnology (2023)
-
The role of noncoding RNAs in metabolic reprogramming of cancer cells
Cellular & Molecular Biology Letters (2023)